Long-Term Durability of the Next-Generation Acurate neo 2 Transcatheter Heart Valve

Transcatheter Aortic Valve Replacement: Current Status and Future Indications

“…Recently, Jorgensen et al reported the 10-year follow-up data from the NOTION trial, which included relatively younger patients with lower surgical risk (mean age 79.1 ± 4.8 years and a mean STS predicted risk of mortality score of 3 ± 1.7%), which showed a significantly lower rate of SVD (20.2% vs. 37.3%, p < 0.05), a greater effective orifice area, and a lower transvalvular gradient in the TAVR group compared to SAVR [23]. Furthermore, ex vivo bench studies have demonstrated favorable hemodynamics simulating up to 25 years of use for the balloon-expandable Sapien 3 THV and the self-expanding ACURATE neo 2 THV (Boston Scientific Corporation, Natick, MA, USA) [24,25].…”

“…To address the issue of THV durability, intraprocedural strategies to optimize valve expansion such as predilatation, appropriate valve sizing, avoidance of postdilatation and newer bioprosthetic platforms including modifications in the leaflet material and designs have been developed which may improve leaflet longevity and THV durability [24,25].…”